ArticleFrontiers in medicine2026
Xanthogranulomatous prostatitis mimicking prostate carcinoma: a case report and comprehensive literature review.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Granulomatous prostatitis (GP) is a relatively uncommon disorder, accounting for approximately 0. 8% to 1.0% of all benign inflammatory prostatic conditions. Xanthogranulomatous prostatitis (XGP) is an exceptionally rare subtype of GP, with only a limited number of cases documented in the medical literature. Clinically and radiologically, this entity often mimics prostatic carcinoma, necessitating histopathological examination for an accurate diagnosis. Case presentation: A 69-year-old man presented with a multi-year history of urinary frequency, nocturia, dysuria, and dull flank pain. Clinical evaluation and laboratory studies revealed an elevated prostate-specific antigen (PSA) level. Ultrasonography demonstrated prostatic enlargement with heterogeneous echogenicity and a 1.7-cm intravesical protrusion. Prostate magnetic resonance imaging (MRI) indicated a prostatic volume of 46.33 cm Conclusion: XGP is an extremely rare prostatic pathology, and histopathological examination remains the gold standard for definitive diagnosis. Conservative management and TURP constitute the recommended therapeutic approaches for this condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.